` 688321 (Shenzhen Chipscreen Biosciences Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

688321
vs
S
Shanghai Composite

Over the past 12 months, Shenzhen Chipscreen Biosciences Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +108% compared to the Shanghai Composite's +18% growth.

Stocks Performance
688321 vs Shanghai Composite

Loading
688321
Shanghai Composite
Add Stock
www.alphaspread.com

Performance Gap
688321 vs Shanghai Composite

Performance Gap Between 688321 and SSEC
HIDDEN
Show

Performance By Year
688321 vs Shanghai Composite

Loading
688321
Shanghai Composite
Add Stock

Competitors Performance
Shenzhen Chipscreen Biosciences Co Ltd vs Peers

Shanghai Composite
688321
LLY
JNJ
NOVO B
ROG
Add Stock

Shenzhen Chipscreen Biosciences Co Ltd
Glance View

Market Cap
14.6B CNY
Industry
Pharmaceuticals

In the bustling city of Shenzhen, often hailed as China's Silicon Valley, Shenzhen Chipscreen Biosciences Co Ltd stands as a testament to innovation in the biopharmaceutical landscape. Founded in 2001, the company embarked on a journey to bridge the gap between cutting-edge bioscience and market needs, focusing on research, development, and commercialization of novel drugs. Chipscreen’s core strength lies in its proprietary chemical genomics-based discovery and development platform, which has carved out a niche in identifying molecular targets and mining drug candidates with high therapeutic potential. The company seamlessly integrates advanced technologies with biotech prowess to design and develop small molecule drugs that address unmet clinical needs, primarily focusing on oncology, autoimmune diseases, and metabolic disorders. The financial engine of Chipscreen Biosciences hums through a well-orchestrated portfolio strategy. By progressing drug candidates through various stages of clinical trials, the company has not only diversified its offerings but also strategically positioned itself in lucrative therapeutic markets. Its revenue model capitalizes on successful product commercialization, primarily through sales of its marketed drugs and royalties from licensing agreements with strategic partners. This collaborative approach enables Chipscreen to maximize its product reach while sharing developmental risks. As the company's innovative therapies gain traction in domestic and global markets, Chipscreen continues its commitment to reinvest in research and development, crafting a sustainable cycle of growth fueled by scientific advancement and strategic acumen.

Shenzhen Chipscreen Biosciences Co Ltd Intrinsic Value
HIDDEN
Show
Back to Top